New transition state-based inhibitor for human ornithine decarboxylase inhibits growth of tumor cells

Molecular Cancer Therapeutics

Volumn 6, Issue 6, 2007, Pages 1831-1839

  Wu, Fang ^a   Grossenbacher, Doris ^a   Gehring, Heinz ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BROPARESTROL; ORNITHINE DECARBOXYLASE; ORNITHINE DERIVATIVE; PYRIDOXYL ORNITHINE; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN COS7; CONTROLLED STUDY; CORRELATION FUNCTION; CRYSTAL STRUCTURE; DNA SYNTHESIS; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; LUNG SMALL CELL CANCER; MOLECULAR MODEL; MYELOMA CELL; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TUMOR GROWTH;

CELL DIVISION; DNA REPLICATION; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; ORNITHINE DECARBOXYLASE;

EID: 34250736331     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0045     Document Type: Article

References (41)

1. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
2. Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem 2006;281:14529-32.
3. Nickel KP, Belury MA. Inositol hexaphosphate reduces 12-O- tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase independent of protein kinase C isoform expression in keratinocytes. Cancer Lett 1999;140:105-11.
4. Glikman P, Manni A, Demers L, Bartholomew M. Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture. Cancer Res 1989;49:1371-6.
5. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 2003;4:537-64.
6. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992;360:355-8.
7. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005;7:433-44.
8. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by α-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. Cancer Res 2003;63:3037-42.
9. Vlastos AT, West LA, Atkinson EN, et al. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res 2005;11:390-6.
10. Casero RA, Jr., Frydman B, Stewart TM, Woster PM. Significance of targeting polyamine metabolism as an antineoplastic strategy: unique targets for polyamine analogues. Proc West Pharmacol Soc 2005;48:24-30.
11. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 1995;35:55-91.
12. Eliot AC, Kirsch JF. Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations. Annu Rev Biochem 2004;73:383-415.
13. Christen P, Mehta PK. From cofactor to enzymes. The molecular evolution of pyridoxal-5′-phosphate-dependent enzymes. Chem Rec 2001;1:436-47.
14. Raso V, Stollar BD. The antibody-enzyme analogy. Characterization of antibodies to phosphopyridoxyltyrosine derivatives. Biochemistry 1975;14:584-91.
15. Heller JS, Canellakis ES, Bussolotti DL, Coward JK. Potent inhibition of ornithine decarboxylase by N-(5′-phosphopyridoxyl)-ornithine. Biochim Biophys Acta 1975;403:197-207.
16. Khomutov RM, Dixon HB, Vdovina LV, et al. N-(5′- Phosphopyridoxyl) glutamic acid and N-(5′-phosphopyridoxyl)-2- oxopyrrolidine-5-carboxylic acid and their action on the apoenzyme of aspartate aminotransferase. Biochem J 1971;124:99-106.
17. Elbert A, Peterson HAS. Preparation of Crystalline Phosphorylated Derivatives of Vitamin B6. J Am Chem Soc 1954;76:169-75.
18. Geistlich A, Gehring H. CDGF (chicken embryofibro blast-derived growth factor) is mitogenically related to TGF-β and modulates PDGF, bFGF, and IGF-I action on sparse NIH/3T3 cells. Exp Cell Res 1993;204:329-35.
19. Koga T, Nakano S, Nakayama M, et al. Identification and partial purification of a low-molecular-weight growth inhibitor formed by density-inhibited, tumorigenic V79 Chinese hamster cells. Cancer Res 1986;46:4431-7.
20. Gerhauser C, Mar W, Lee SK, et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med 1995;1:260-6.
21. Belyanskaya LL, Delattre O, Gehring H. Expression and subcellular localization of Ewing sarcoma (EWS) protein is affected by the methylation process. Exp Cell Res 2003;288:374-81.
22. Nasizadeh S, Myhre L, Thiman L, et al. Importance of polyamines in cell cycle kinetics as studied in a transgenic system. Exp Cell Res 2005;308:254-64.
23. Dai H, Kramer DL, Yang C, et al. The polyamine oxidase inhibitor MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects. Cancer Res 1999;59:4944-54.
24. Almrud JJ, Oliveira MA, Kern AD, et al. Crystal structure of human ornithine decarboxylase at 2.1 A resolution: structural insights to antizyme binding. J Mol Biol 2000;295:7-16.
25. Jackson LK, Brooks HB, Osterman AL, Goldsmith EJ, Phillips MA. Altering the reaction specificity of eukaryotic ornithine decarboxylase. Biochemistry 2000;39:11247-57.
26. Kuntz ID. Structure-based strategies for drug design and discovery. Science 1992;257:1078-82.
27. Bohm HJ. A novel computational tool for automated structure-based drug design. J Mol Recognit 1993;6:131-7.
28. Heiskala M, Zhang J, Hayashi S, Holtta E, Andersson LC. Translocation of ornithine decarboxylase to the surface membrane during cell activation and transformation. EMBO J 1999;18:1214-22.
29. Pomidor MM, Ruhl KK, Zheng P, et al. Relationship between ornithine decarboxylase and cytoskeletal organization in cultured human keratinocytes: cellular responses to phorbol esters, cytochalasins, and α- difluoromethylornithine. Exp Cell Res 1995;221:426-37.
30. Zhang Z, McCormick DB. Uptake and metabolism of N-(4′- pyridoxyl) amines by isolated rat liver cells. Arch Biochem Biophys 1992;294:394-7.
31. Zhang ZM, McCormick DB. Uptake of N-(4′-pyridoxyl)amines and release of amines by renal cells: a model for transporter-enhanced delivery of bioactive compounds. Proc Natl Acad Sci U S A 1991;88:10407-10.
32. Ogier G, Chantepie J, Deshayes C, et al. Contribution of 4-methylthio-2-oxobutanoate and its transaminase to the growth of methionine-dependent cells in culture. Effect of transaminase inhibitors. Biochem Pharmacol 1993;45:1631-44.
33. Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005;280:31220-9.
34. Robson LC, Schwarz MR. in Vitamin B6 metabolism and role in growth. Tryfiates GP, editor. Westport (CT): Food and Nutrition Press; 1980. p. 205.
35. Wallace HM, Fraser AV. Inhibitors of polyamine metabolism: review article. Amino Acids 2004;26:353-65.
36. Delcros JG, Tomasi S, Carrington S, et al. Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine. J Med Chem 2002;45:5098-111.
37. Qu N, Ignatenko NA, Yamauchi P, et al. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J 2003;375:465-70.
38. 1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 2000;275:38319-28.
39. Duranton B, Holl V, Schneider Y, et al. Cytotoxic effects of the polyamine oxidase inactivator MDL 72527 to two human colon carcinoma cell lines SW480 and SW620. Cell Biol Toxicol 2002;18:381-96.
40. Eugene Kellogg G, Abraham DJ. Hydrophobicity: is LogP(o/w) more than the sum of its parts? Eur J Med Chem 2000;35:651-61.
41. Hui AM, Zhang W, Chen W, et al. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res 2004;64:9115-23.